^
Association details:
| Biomarker: | ZKSCAN1-BRAF fusion |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An oncogenic Ezh2 mutation cooperates with particular genetic alterations to induce tumors in mice and redistributes H3K27 trimethylation throughout the genome
Excerpt:
A Spitzoid melanoma from a 46‐year‐old Caucasian woman that harbored a ZKSCAN1‐BRAF fusion responded to treatment with the MEK inhibitor trametinib given at full dose (2 mg/day orally) (Case 38) (Fig. (Fig.4).4).
DOI:
10.1038/nm.4092
